Home positive
 

Keywords :   


Tag: positive

MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma

2014-11-16 10:25:00| Merck.com - Research & Development News

Dateline City: ZURICH Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed pembrolizumab, the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab- Language: English Contact: MSDMedia:Lainie Keller, +1-908-236-5036Claire Mulhearn, +1-908-236-1118orInvestor:Joseph Romanelli, +1-908-423-5185Justin Holko, +1-908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with advanced study positive

 

Merck Announces Positive Study Investigating the Use of KEYTRUDA (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma

2014-11-16 10:25:00| Merck.com - Research & Development News

Dateline City: ZURICH KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with advanced study positive

 
 

Retail sales bounce back in October in positive sign for holiday season

2014-11-15 06:38:52| Grocery - Topix.net

An employee stocks bottles of wine at a Whole Foods Market in Dublin, Ohio, on Nov. 7. A 0.3% rise in retail sales last month after a September drop bodes well for a strong holiday shopping season Retail sales bounced back last month after a disappointing September drop, providing positive consumer-spending momentum heading into the holiday shopping season. Lower gasoline prices helped put consumers in the spending mood, said Jack Kleinhenz, chief economist at the National Retail Federation.

Tags: back sign october sales

 

Industry takes positive step to sustainable fashion

2014-11-14 12:27:00| Daily apparel & textile news and comment - from just-style.com

Fashion designers, brands and suppliers including Stella McCartney, G-Star Raw, Bionic Yarn, Loomstate and Saitex have joined a new sustainability initiative aimed at helping businesses improve the way clothes are made and spurring the creation of more eco-friendly materials.

Tags: industry step positive takes

 

Advanced Photonix, Inc. Reports Continued Revenue Growth And Positive EBITDA

2014-11-11 20:18:33| Semiconductors - Topix.net

Gross profit margin for Q2 FY2015 was 33.7% of sales compared to 37.0% for the second quarter ended . The lower gross profit percentage has been driven by the growing mix of 100G HSOR product sales at competitively priced levels and a decline in Terahertz revenue.

Tags: advanced reports positive growth

 

Sites : [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] next »